A detailed history of Sei Investments CO transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Sei Investments CO holds 41,758 shares of PTGX stock, worth $1.41 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
41,758
Previous 37,229 12.17%
Holding current value
$1.41 Million
Previous $853,000 41.62%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 07, 2024

BUY
$21.79 - $32.15 $98,686 - $145,607
4,529 Added 12.17%
41,758 $1.21 Million
Q4 2023

Feb 14, 2024

SELL
$14.05 - $23.44 $41,967 - $70,015
-2,987 Reduced 7.43%
37,229 $853,000
Q3 2023

Nov 14, 2023

SELL
$16.68 - $23.66 $530,424 - $752,388
-31,800 Reduced 44.16%
40,216 $670,000
Q2 2023

Aug 11, 2023

BUY
$18.02 - $29.36 $655,513 - $1.07 Million
36,377 Added 102.07%
72,016 $1.99 Million
Q1 2023

May 12, 2023

SELL
$10.78 - $25.38 $3,298 - $7,766
-306 Reduced 0.85%
35,639 $819,000
Q4 2022

Feb 10, 2023

SELL
$7.36 - $11.17 $4,541 - $6,891
-617 Reduced 1.69%
35,945 $392,000
Q3 2022

Nov 14, 2022

SELL
$7.86 - $11.71 $663,721 - $988,827
-84,443 Reduced 69.78%
36,562 $308,000
Q2 2022

Aug 15, 2022

SELL
$7.06 - $25.52 $68,573 - $247,875
-9,713 Reduced 7.43%
121,005 $957,000
Q1 2022

May 13, 2022

SELL
$23.34 - $36.08 $37,227 - $57,547
-1,595 Reduced 1.21%
130,718 $3.1 Million
Q4 2021

Feb 14, 2022

BUY
$17.63 - $37.1 $1.52 Million - $3.2 Million
86,138 Added 186.55%
132,313 $4.53 Million
Q3 2021

Nov 12, 2021

SELL
$12.95 - $49.69 $781,649 - $3 Million
-60,359 Reduced 56.66%
46,175 $818,000
Q2 2021

Aug 06, 2021

BUY
$25.57 - $44.88 $502,552 - $882,071
19,654 Added 22.62%
106,534 $4.78 Million
Q1 2021

May 12, 2021

BUY
$19.02 - $31.15 $1.65 Million - $2.71 Million
86,880 New
86,880 $2.25 Million

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $1.66B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Sei Investments CO Portfolio

Follow Sei Investments CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sei Investments CO, based on Form 13F filings with the SEC.

News

Stay updated on Sei Investments CO with notifications on news.